Neurology News

Quanterix Corporation announced the launch of LucentAD, a test to assist in the evaluation of patients experiencing cognitive symptoms consistent with signs of early Alzheimer’s disease.

AUSTIN, Texas – Children and adolescents diagnosed with anxiety, depression or both had greater headache-related disability compared with those without, according to a poster presented at the American Headache Society annual meeting.

Higher daily intake of dietary caffeine was associated with an increased prevalence of severe headache or migraine in adults, particularly women, according to researchers.

Edgewise Therapeutics Inc. announced positive 12-month topline results from the ARCH study evaluating the safety, tolerability and pharmacokinetics of EDG-5506 in adults with Becker muscular dystrophy.

Reata Pharmaceuticals announced that Skyclarys is now commercially available for patients older than 16 years who have Friedreich’s ataxia, a rare degenerative neuromuscular disorder that manifests at a young age.

The FDA has granted Eisai full approval for Leqembi to treat adults with Alzheimer’s disease.

Annovis Bio announced it received a positive safety review from an independent Data and Safety Monitoring Board for its phase 3 trial of buntanetap, a drug for treatment of patients with early Parkinson’s disease.

AUSTIN, Texas — Migraine significantly affects work life and career in Canadian residents, with greater effect among those with more headache days per month, according to a poster at the American Headache Society annual meeting.

AUSTIN, Texas — One in five individuals with migraine used opioids or kept them on hand for treatment, with 83% reporting at least 1 day of opioid use in the past 30 days, according to Richard B. Lipton, MD, in this Healio video.

The FDA has declined to approve Amneal Pharmaceuticals’ new drug application for IPX203, a novel, oral formulation of extended-release carbidopa/levodopa designed for the treatment of Parkinson’s disease.